Search Results - "Troy, Ella C"

Results of a phase I trial with Haploidentical mbIL‐21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML by Ciurea, Stefan O., Kongtim, Piyanuch, Srour, Samer, Chen, Julianne, Soebbing, Doris, Shpall, Elizabeth, Rezvani, Katayoun, Nakkula, Robin, Thakkar, Aarohi, Troy, Ella C., Cash, Alex A., Behbehani, Gregory, Cao, Kai, Schafer, Jolie, Champlin, Richard E., Lee, Dean A.

“…Natural killer (NK)‐cells have potent anti‐tumor effects, yet it remains unclear if they are effective for patients with relapsed acute myeloid leukemia (AML)…”
Get full text

CD38 KO/CD38-CAR Human Primary Natural Killer Cells Enhance Cytotoxicity Against CD38-Expressing Primary Lymphoma, Leukemia, and Myeloma by Troy, Ella C, Sezgin, Yasemin, Pereira, Marcelo De Souza, Caporale, Joseph, Behbehani, Gregory K, Lyberger, Justin, Lee, Dean Anthony, Naeimi Kararoudi, Meisam

“…Natural killer (NK) cells have strong cancer immunotherapeutic potential that can be further augmented by engineering with a chimeric antigen receptor (CAR)…”
Get full text

SAR445419 Off-the-Shelf Natural Killer Cells Are Safe and Show Efficacy Signal in Relapsed/Refractory Acute Myeloid Leukemia by Vasu, Sumithira, Szuminski, Nicole, Saad, Ayman, Wall, Sarah A., Blachly, James, Behbehani, Gregory, Larkin, Karilyn, Bezerra, Evandro, Sanchez-Petito, Gabriela, Choe, Hannah, Denlinger, Nathan, Nakkula, Robin J, Troy, Ella C, de Lima, Marcos, ODonnell, Lynn, Lee, Dean

“…Natural Killer (NK) cells are cytotoxic lymphocytes that exert an anti-tumor effect in an MHC-I independent manner but are dysfunctional and reduced in number…”
Get full text

276 - A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Third-Party Donor-Derived Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome by Vasu, Sumithira, Sharma, Nidhi, Walker, Alison, Wall, Sarah A., Blachly, James, Behbehani, Gregory, Choe, Hannah, Thakkar, Aarohi, Nakkula, Robin J, Troy, Ella C, Szuminski, Nicole, De Lima, Marcos, ODonnell, Lynn, Lee, Dean Anthony

Get full text

A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Third-Party Donor-Derived Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome by Vasu, Sumithira, Sharma, Nidhi, Walker, Alison, Wall, Sarah A., Blachly, James, Behbehani, Gregory, Choe, Hannah, Thakkar, Aarohi, Nakkula, Robin J, Troy, Ella C, Szuminski, Nicole, De Lima, Marcos, ODonnell, Lynn, Lee, Dean Anthony

Get full text